You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 2, 2024

~ Buy the LUMAKRAS (sotorasib) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR LUMAKRAS

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for LUMAKRAS

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05054725 ↗	Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies	Recruiting	Amgen	Phase 2	2021-10-01	The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
NCT05054725 ↗	Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies	Recruiting	Sanofi	Phase 2	2021-10-01	The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
NCT05054725 ↗	Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies	Recruiting	Revolution Medicines, Inc.	Phase 2	2021-10-01	The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
NCT05251038 ↗	Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer	Not yet recruiting	Amgen	Phase 1/Phase 2	2022-05-01	This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety, tolerability and efficacy of sotorasib in combination with chemotherapy for patients with advanced KRAS p.G12C mutant pancreatic cancer with progression of disease after first line treatment. There will be a safety lead in to determine the safety and tolerability of the sotorasib in combination with standard chemotherapy. A Simon two-stage design will be employed to evaluate the efficacy of sotorasib in combination with standard of care second line chemotherapy.
NCT05251038 ↗	Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer	Not yet recruiting	Devalingam Mahalingam	Phase 1/Phase 2	2022-05-01	This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety, tolerability and efficacy of sotorasib in combination with chemotherapy for patients with advanced KRAS p.G12C mutant pancreatic cancer with progression of disease after first line treatment. There will be a safety lead in to determine the safety and tolerability of the sotorasib in combination with standard chemotherapy. A Simon two-stage design will be employed to evaluate the efficacy of sotorasib in combination with standard of care second line chemotherapy.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for LUMAKRAS

Condition Name

Chart
Table

Condition Name for LUMAKRAS
Intervention	Trials
Non-small Cell Lung Cancer	2
Advanced Malignant Solid Neoplasm	1
KRAS P.G12C	1
Metastatic Malignant Solid Neoplasm	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for LUMAKRAS
Intervention	Trials
Lung Neoplasms	2
Carcinoma, Non-Small-Cell Lung	2
Pancreatic Neoplasms	1
Neoplasms	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for LUMAKRAS

Trials by Country

Map
Table

Trials by Country for LUMAKRAS
Location	Trials
United States	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for LUMAKRAS
Location	Trials
New York	1
Maryland	1
Georgia	1
Connecticut	1
California	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for LUMAKRAS

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for LUMAKRAS
Clinical Trial Phase	Trials
Phase 2	2
Phase 1/Phase 2	1
Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for LUMAKRAS
Clinical Trial Phase	Trials
Not yet recruiting	3
Recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LUMAKRAS

Sponsor Name

Chart
Table

Sponsor Name for LUMAKRAS
Sponsor	Trials
Amgen	2
Sanofi	1
Revolution Medicines, Inc.	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for LUMAKRAS
Sponsor	Trials
Industry	5
Other	2
NIH	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.